痴呆病人血小板5-羟色胺浓度初探

Preliminary research on serotonin platelet level in Alzheimer's disease or vascular dementia

目的：探讨痴呆病人5-羟色羟(5-HT,血清素)水平与病情严重程度、精神行为症状之间的关系。方法：将痴呆病人分为阿尔采末病(AD)组、血管性痴呆(VaD)组,对照组为无明显认知损害的精神分裂症老年病人,采集病人外周血4mL测定血小板5-HT浓度。同时采用简易智力状态检查(MMSE)、神经精神科问卷(NPI)和临床大体印象评定量表(CGI)等对病人进行评估。结果：共入组AD病人22例、VaD病人10例及精神分裂症病人10例；3组病人血小板5-HT浓度比较无显著差异(P＞0．05)；血小板5-HT浓度与年龄、性别、用药情况、MMSE和NPI评分不相关(P＞0．05)。结论：总体5-HT水平与认知损害不直接相关,不能作为痴呆病人的精神行为与疾病严重程度的生物学标志。

AIM： To evaluate and explore the relationship between serotonin characters in patients with Alzheimer＇s disease or valcular dementia. METHODS： Alzheimer＇s disease （AD group）, 10 with vascular dementia （VaD group） and 10 platelet level and clinical Twenty-two patients with aged and gender matched control with no cognitive impairment schizophrenia （schizophrenia group） were evaluated with the serotonin platelet levels through measuring the concentration in peripheral blood and were assessed with mini-mental state- ment examination （MMSE）, the neuropsychiatric inventory （NPI） and clinical global impression （CGI）. RESULTS： There were no significant differences of serotonin platelet concentration among the AD group, VaD group and schizophrenia group （P 〉 0.05） , however, a tendency of difference was found between VaD group and the schizophrenia control＇s （P = 0.062）. Further more, the serotonin platelet concentration didn＇t show any correlations to the age, gender, the ongoing medicines and any scores of MMSE, NPI and CGI （P 〉 0.05） . CONCLUSION： The total serotonin level is not directly related to cognitive impairment and thus can＇t be a biomarker to evaluate the neuropsychiatric symptoms and severity of Alzheimer＇s disease or vascular dementia.